Organised by EARTO & EIRMA - Hosted by Luxembourg Institute of Science andd Technology (LIST)
David Brown has 40 years experience in the pharmaceutical / biotechnology industry both in research and in senior executive roles. He served with 4 of the top 10 pharmaceutical companies: Zeneca, Pfizer, GlaxoWellcome, and Hoffman La-Roche; and also as President and Chief Executive of Cellzome AG, a biotechnology company with headquarters in Heidelberg, Germany. Whilst at Pfizer he was named co-inventor on the patent for Viagra, a treatment for male impotence, and he led the team that developed Viagra through to proof of clinical efficacy in human clinical trials. The drug is also marketed for treatment of pulmonary hypertension under the trade name Revatio. He also had a pivotal role in the discovery of Relpax, a treatment for migraine. Together these drugs have achieved sales of over $30 billion. While at Roche in Switzerland, he was a Director of the company with responsibility for productivity of over 2000 staff focused on drug discovery at Roche’s five research sites in the USA, Europe and Asia.
David Brown has a strong interest in entrepreneurialism. He coaches CEOs and entrepreneurs at the Centre for Entrepreneurial Learning at Cambridge University Business School and he is an Angel Investor in high-technology start-up companies. He has founded or co-founded several biotechnology companies including Crescendo Biologics of which he is currently Chair of the board. He also serves on the boards of Amura Ltd (Chair), ProFactor Pharma Ltd (Chair) and Babraham Institute Enterprise Ltd (Chair). He serves on the Technology Transfer Strategy Panel of the Wellcome Trust, London, which provides governance oversight and guidance on strategic direction for the Trust's grant-awarding bodies.